老人用医薬品の世界市場レポート 2025年

老人用医薬品の市場規模は今後数年で急成長が見込まれます。2029年にはCAGR16.2％で2兆6,048億6,000万米ドルに成長します。予測期間に予測される成長は、加齢に関連した健康状態の有病率の増加、老人人口の増加、医療費の増加、老人医療の拡大、高血圧の罹患率の増加といった要因に起因しています。この期間に予想される主な動向には、デジタルピルやウェアラブル健康機器の使用、複数の薬剤を安全に管理するツールや戦略の開発、幹細胞・遺伝子治療の進歩、遠隔医療プラットフォームの利用拡大、加齢関連疾患の早期診断と予防におけるイノベーションなどがあります。

老人用医薬品市場の成長は、加齢に関連した健康状態の有病率の上昇によって牽引されると予想されます。これらの疾患は、加齢とともに一般的になったり重篤化したりするが、これは主に自然な老化プロセスによるものです。平均寿命の伸び、ヘルスケアの進歩、高齢者人口の増加といった要因が、こうした健康問題の発生を高めています。老人用医薬品は、このような加齢に関連した症状を管理する上で極めて重要であり、高齢者のQOLとヘルスケアの成果を高める専門的な治療を提供しています。例えば、OHID（Office for Health Improvement and Disparities）が2023年3月に発表した報告書によると、英国では2022年に16歳以上の17.6％が関節炎や慢性関節障害などの長期的な筋骨格系（MSK）疾患を有すると報告されています。これは2021年の17.0％から増加しています。その結果、加齢に関連した健康状態の有病率の上昇が老人用医薬品市場の成長を促進しています。

老人用医薬品市場の主要企業は、高齢化社会における効果的な治療に対する需要の高まりに対応するため、革新的な糖尿病治療の開発に注力しています。糖尿病治療には、安全性、有効性、患者の転帰の面で従来の方法を上回ることを目指し、管理を改善したり、治癒の可能性を提供したりする最先端の治療法が含まれます。例えば、2023年8月、インドの製薬会社Akums Drugs &Pharmaceuticals Ltd.は、ビルダグリプチンSRとメトホルミンSRの新しい併用療法を発表しました。この新製剤は、高齢者の2型糖尿病管理に特化して設計されており、血糖コントロールの改善と同時に、低血糖や体重増加など、高齢者にとって特に重要な懸念事項に対処します。本剤は、インスリン分泌を促進し、血糖値を低下させることにより、安全性と有効性を両立させる。本剤はインド医薬品監督庁（DCGI）の承認を取得しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界老人用医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の老人用医薬品市場：成長率分析
• 世界の老人用医薬品市場の実績：規模と成長, 2019-2024
• 世界の老人用医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界老人用医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の老人用医薬品市場セラピューティクス社、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鎮痛剤
• 降圧剤
• スタチン
• プロトンポンプ阻害剤
• 抗凝固剤
• 抗精神病薬
• その他の治療薬
• 世界の老人用医薬品市場状態別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 心血管系
• 関節炎
• 神経学的
• がん
• 骨粗鬆症
• 呼吸器
• その他の条件
• 世界の老人用医薬品市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の老人用医薬品市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の老人用医薬品市場鎮痛剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非オピオイド鎮痛剤（アセトアミノフェン、NSAIDs）
• オピオイド鎮痛剤（モルヒネ、オキシコドン）
• 局所鎮痛剤（リドカインパッチ）
• 世界の老人用医薬品市場降圧剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンジオテンシン変換酵素（ACE）阻害剤
• アンジオテンシンII受容体拮抗薬（ARB）
• ベータ遮断薬
• カルシウムチャネル遮断薬
• 利尿剤
• アルファ遮断薬
• 世界の老人用医薬品市場スタチンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アトルバスタチン
• シンバスタチン
• ロスバスタチン
• プラバスタチン
• ロバスタチン
• 世界の老人用医薬品市場プロトンポンプ阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• オメプラゾール
• エソメプラゾール
• ランソプラゾール
• パントプラゾール
• ラベプラゾール
• 世界の老人用医薬品市場抗凝固剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ワルファリン
• 直接経口抗凝固薬（DOAC）：ダビガトラン、リバーロキサバン、アピキサバン
• ヘパリン
• 世界の老人用医薬品市場抗精神病薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非定型抗精神病薬
• 定型抗精神病薬
• 世界の老人用医薬品市場その他の治療薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗うつ薬（SSRI、SNRI）
• 抗糖尿病薬（インスリン、メトホルミン）
• 抗けいれん薬
• 抗炎症薬（コルチコステロイド）
• 認知機能向上薬（ドネペジル、メマンチン）

第7章 地域別・国別分析

• 世界の老人用医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の老人用医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 老人用医薬品市場：競合情勢
• 老人用医薬品市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Boehringer Ingelheim GmbH
• Regeneron Pharmaceuticals Inc.
• Macleods Pharmaceuticals Ltd.
• Apotex Inc.
• Intas Pharmaceuticals Limited
• Dr. Reddy's Laboratories
• Lupin Limited
• Biocon Limited
• Torrent Pharmaceuticals Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 老人用医薬品市場2029：新たな機会を提供する国
• 老人用医薬品市場2029：新たな機会を提供するセグメント
• 老人用医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Geriatric medicines are medications specifically prescribed for individuals aged 65 and older, addressing their unique health needs. These medications are formulated to support cognitive function, mobility, and immune health while taking into account the physiological changes that impact drug metabolism in older adults. They are commonly used to manage chronic conditions and age-related symptoms, ultimately enhancing the overall quality of life for the elderly.

The main therapeutics used in geriatric medicines include analgesics, antihypertensives, statins, proton pump inhibitors, anticoagulants, antipsychotics, and others. Analgesics are essential in geriatric care to manage chronic pain, improve mobility, and enhance the quality of life. These medications are applied in various conditions such as cardiovascular disease, arthritis, neurological disorders, cancer, osteoporosis, and respiratory issues, among others. They are administered through different routes, including oral, parenteral, and others, and are distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The geriatric medicines market research report is one of a series of new reports from The Business Research Company that provides geriatric medicines market statistics, including the geriatric medicines industry global market size, regional shares, competitors with the geriatric medicines market share, detailed geriatric medicines market segments, market trends, and opportunities, and any further data you may need to thrive in the geriatric medicines industry. These geriatric medicines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The geriatric medicines market size has grown rapidly in recent years. It will grow from $1,227.91 billion in 2024 to $1,430.84 billion in 2025 at a compound annual growth rate (CAGR) of 16.5%. The growth observed during the historic period can be attributed to factors such as the increasing prevalence of stroke, the rising incidence of chronic diseases, a growing prevalence of cardiovascular diseases, increased government support, and a heightened emphasis on personalized medicine.

The geriatric medicines market size is expected to see rapid growth in the next few years. It will grow to $2,604.86 billion in 2029 at a compound annual growth rate (CAGR) of 16.2%. The growth projected for the forecast period can be attributed to factors such as the increasing prevalence of age-related health conditions, a growing geriatric population, rising healthcare expenditures, the expansion of geriatric medicine, and a higher incidence of hypertension. Key trends expected during this period include the use of digital pills and wearable health devices, the development of tools and strategies to manage multiple medications safely, advancements in stem cell and gene therapy, the expanded use of telehealth platforms, and innovations in early diagnosis and prevention of age-related diseases.

The growth of the geriatric medicines market is expected to be driven by the rising prevalence of age-related health conditions. These conditions become more common or severe with aging, largely due to the natural aging process. Factors such as increased life expectancy, advancements in healthcare, and a growing elderly population contribute to the higher occurrence of these health issues. Geriatric medicines are crucial in managing these age-related conditions, offering specialized treatments that enhance the quality of life and healthcare outcomes for older individuals. For example, a report by the Office for Health Improvement and Disparities (OHID) in March 2023 revealed that 17.6% of individuals aged 16 and older in the UK reported having a long-term musculoskeletal (MSK) condition, such as arthritis or chronic joint problems, in 2022. This represents an increase from 17.0% in 2021. Consequently, the rising prevalence of age-related health conditions is propelling the growth of the geriatric medicines market.

Leading companies in the geriatric medicines market are focusing on developing innovative diabetes therapies to meet the growing demand for effective treatments in the aging population. Diabetes therapy involves cutting-edge treatments that improve management or offer potential cures, aiming to surpass traditional methods in terms of safety, efficacy, and patient outcomes. For example, in August 2023, Akums Drugs & Pharmaceuticals Ltd., a pharmaceutical company based in India, introduced a novel combination therapy of Vildagliptin SR and Metformin SR. This new formulation is designed specifically to manage Type 2 diabetes in elderly patients, offering improved glycemic control while addressing key concerns such as hypoglycemia and weight gain, which are especially important for this group. The combination works by enhancing insulin secretion and lowering blood sugar levels, providing both safety and effectiveness. The product has been approved by the Drug Controller General of India (DCGI).

In October 2023, Zydus Pharmaceuticals UK Limited, a pharmaceutical company based in the UK, acquired LiqMeds Group for an undisclosed sum. This acquisition is intended to strengthen Zydus Life Sciences' position in the expanding oral liquid products market, addressing the specific needs of geriatric and pediatric patients. LiqMeds Group, also based in the UK, specializes in oral liquid formulations, which are particularly advantageous for elderly patients.

Major players in the geriatric medicines market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Apotex Inc., Intas Pharmaceuticals Limited, Dr. Reddy's Laboratories, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., and Endo Pharmaceuticals Inc.

North America was the largest region in the geriatric medicines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in geriatric medicines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the geriatric medicines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The geriatric medicines market consists of sales of antidepressants, diuretics, antidiabetics, and anticonvulsants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Geriatric Medicines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on geriatric medicines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for geriatric medicines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The geriatric medicines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Analgesics; Antihypertensive; Statins; Proton Pump Inhibitors; Anticoagulant; Antipsychotic; Other Therapeutics
• 2) By Condition: Cardiovascular; Arthritis; Neurological; Cancer; Osteoporosis; Respiratory; Other Conditions
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Analgesics: Non-Opioid Analgesics (Acetaminophen, NSAIDs); Opioid Analgesics (Morphine, Oxycodone); Topical Analgesics (Lidocaine Patches)
• 2) By Antihypertensive: Angiotensin-Converting Enzyme (ACE) Inhibitors; Angiotensin II Receptor Blockers (ARBs); Beta-Blockers; Calcium Channel Blockers; Diuretics; Alpha-Blockers
• 3) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin; Lovastatin
• 4) By Proton Pump Inhibitors: Omeprazole; Esomeprazole; Lansoprazole; Pantoprazole; Rabeprazole
• 5) By Anticoagulant: Warfarin; Direct Oral Anticoagulants (DOACs): Dabigatran, Rivaroxaban, Apixaban; Heparin
• 6) By Antipsychotic: Atypical Antipsychotics; Typical Antipsychotics
• 7) By Other Therapeutics: Antidepressants (SSRIs, SNRIs); Antidiabetic Medications (Insulin, Metformin); Anticonvulsants; Anti-Inflammatory Drugs (Corticosteroids); Cognitive Enhancers (Donepezil, Memantine)
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Geriatric Medicines Market Characteristics

3. Geriatric Medicines Market Trends And Strategies

4. Geriatric Medicines Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Geriatric Medicines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Geriatric Medicines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Geriatric Medicines Market Growth Rate Analysis
• 5.4. Global Geriatric Medicines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Geriatric Medicines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Geriatric Medicines Total Addressable Market (TAM)

6. Geriatric Medicines Market Segmentation

• 6.1. Global Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Analgesics
• Antihypertensive
• Statins
• Proton Pump Inhibitors
• Anticoagulant
• Antipsychotic
• Other Therapeutics
• 6.2. Global Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cardiovascular
• Arthritis
• Neurological
• Cancer
• Osteoporosis
• Respiratory
• Other Conditions
• 6.3. Global Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Geriatric Medicines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Geriatric Medicines Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Opioid Analgesics (Acetaminophen, NSAIDs)
• Opioid Analgesics (Morphine, Oxycodone)
• Topical Analgesics (Lidocaine Patches)
• 6.6. Global Geriatric Medicines Market, Sub-Segmentation Of Antihypertensive, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Angiotensin-Converting Enzyme (ACE) Inhibitors
• Angiotensin II Receptor Blockers (ARBs)
• Beta-Blockers
• Calcium Channel Blockers
• Diuretics
• Alpha-Blockers
• 6.7. Global Geriatric Medicines Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Simvastatin
• Rosuvastatin
• Pravastatin
• Lovastatin
• 6.8. Global Geriatric Medicines Market, Sub-Segmentation Of Proton Pump Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Omeprazole
• Esomeprazole
• Lansoprazole
• Pantoprazole
• Rabeprazole
• 6.9. Global Geriatric Medicines Market, Sub-Segmentation Of Anticoagulant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Warfarin
• Direct Oral Anticoagulants (DOACs): Dabigatran, Rivaroxaban, Apixaban
• Heparin
• 6.10. Global Geriatric Medicines Market, Sub-Segmentation Of Antipsychotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atypical Antipsychotics
• Typical Antipsychotics
• 6.11. Global Geriatric Medicines Market, Sub-Segmentation Of Other Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antidepressants (SSRIs, SNRIs)
• Antidiabetic Medications (Insulin, Metformin)
• Anticonvulsants
• Anti-Inflammatory Drugs (Corticosteroids)
• Cognitive Enhancers (Donepezil, Memantine)

7. Geriatric Medicines Market Regional And Country Analysis

• 7.1. Global Geriatric Medicines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Geriatric Medicines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Geriatric Medicines Market

• 8.1. Asia-Pacific Geriatric Medicines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Geriatric Medicines Market

• 9.1. China Geriatric Medicines Market Overview
• 9.2. China Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Geriatric Medicines Market

• 10.1. India Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Geriatric Medicines Market

• 11.1. Japan Geriatric Medicines Market Overview
• 11.2. Japan Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Geriatric Medicines Market

• 12.1. Australia Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Geriatric Medicines Market

• 13.1. Indonesia Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Geriatric Medicines Market

• 14.1. South Korea Geriatric Medicines Market Overview
• 14.2. South Korea Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Geriatric Medicines Market

• 15.1. Western Europe Geriatric Medicines Market Overview
• 15.2. Western Europe Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Geriatric Medicines Market

• 16.1. UK Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Geriatric Medicines Market

• 17.1. Germany Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Geriatric Medicines Market

• 18.1. France Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Geriatric Medicines Market

• 19.1. Italy Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Geriatric Medicines Market

• 20.1. Spain Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Geriatric Medicines Market

• 21.1. Eastern Europe Geriatric Medicines Market Overview
• 21.2. Eastern Europe Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Geriatric Medicines Market

• 22.1. Russia Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Geriatric Medicines Market

• 23.1. North America Geriatric Medicines Market Overview
• 23.2. North America Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Geriatric Medicines Market

• 24.1. USA Geriatric Medicines Market Overview
• 24.2. USA Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Geriatric Medicines Market

• 25.1. Canada Geriatric Medicines Market Overview
• 25.2. Canada Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Geriatric Medicines Market

• 26.1. South America Geriatric Medicines Market Overview
• 26.2. South America Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Geriatric Medicines Market

• 27.1. Brazil Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Geriatric Medicines Market

• 28.1. Middle East Geriatric Medicines Market Overview
• 28.2. Middle East Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Geriatric Medicines Market

• 29.1. Africa Geriatric Medicines Market Overview
• 29.2. Africa Geriatric Medicines Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Geriatric Medicines Market, Segmentation By Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Geriatric Medicines Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Geriatric Medicines Market Competitive Landscape And Company Profiles

• 30.1. Geriatric Medicines Market Competitive Landscape
• 30.2. Geriatric Medicines Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Geriatric Medicines Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. F. Hoffmann-La Roche AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Viatris Inc.
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Boehringer Ingelheim GmbH
• 31.8. Regeneron Pharmaceuticals Inc.
• 31.9. Macleods Pharmaceuticals Ltd.
• 31.10. Apotex Inc.
• 31.11. Intas Pharmaceuticals Limited
• 31.12. Dr. Reddy's Laboratories
• 31.13. Lupin Limited
• 31.14. Biocon Limited
• 31.15. Torrent Pharmaceuticals Ltd.

32. Global Geriatric Medicines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Geriatric Medicines Market

34. Recent Developments In The Geriatric Medicines Market

35. Geriatric Medicines Market High Potential Countries, Segments and Strategies

• 35.1 Geriatric Medicines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Geriatric Medicines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Geriatric Medicines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer